Genomics

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

TriNetX's acquisition of Zetta Genomics' XetaBase platform promises to accelerate research by integrating genomic and clinical data on a global scale.

A new clinical trial uses multi-ancestry genetic risk scores to see if knowing your DNA can motivate you to prevent heart disease. Here's how it works.

Formerly TT Capital Partners, the independent firm's new identity follows a major fundraise, sharpening its focus on healthcare IT in a competitive market.

For years, doctors dismissed her children's illness. One genetic test changed everything, revealing a truth hidden in their DNA and a flawed system.

A $2.9M investment funds five new projects using DNA and AI to clean up oil sands, secure hydrogen energy, and build a more sustainable future for Alberta.

Agena Bioscience's new test helps labs align with updated ACMG recommendations for cystic fibrosis, aiming for more equitable and efficient carrier screening.

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

New cardiology guidelines now include DNA risk scores, a move poised to revolutionize prevention and spot hidden threats before they strike.

The precision oncology firm reports a dramatic cut in net loss and a strategic pivot paying off, bolstered by a new U.S. patent for its cancer tech.

Genomic Testing Cooperative opens a Houston lab, leveraging the city's elite oncology ecosystem to expand its unique cooperative model for cancer testing.

A new fellowship at the Institut Pasteur aims to revolutionize public health by training scientists in what its founder calls the '3Ms': Money, Management, and Medicine.

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

Zoetis is acquiring Neogen's genomics unit for $160M, a strategic move set to accelerate data-driven innovation in livestock and companion animal care.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

With $28M in funding and a star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.